Dr. Brugge is currently Director of the Harvard Ludwig Cancer Center and Professor of Cell Biology at Harvard Medical School. She received her B.S. degree from Northwestern University, Ph.D. degree from the Baylor College of Medicine, and postdoctoral training at the University of Colorado with Dr. Raymond Erikson. Prior to joining Harvard (Professor 1997-present, Department Chair 2004-2014), Dr. Brugge has held professorship at the State University of New York, Stony Brook (1979- 1988), and was an HHMI investigator/professor at the University of Pennsylvania (1989-1992). Dr. Brugge was also Scientific Director of the biotechnology company ARIAD (1992-1997).
Dr. Brugge has received the NIH Merit Award, American Cancer Society Research Professorship, ASCB Senior Career Recognition Award, as well as elected memberships in the American Academy of Arts and Sciences, National Academy of Sciences, and the Institute of Medicine.
Michele Atlan has been a breast cancer survivor since 2013. After her diagnosis, Michele became certified as an Emergency Medical Technician. She graduated from the National Breast Cancer Coalition’s (NBCC) Project LEAD in 2015 and participated in the San Antonio Breast Cancer Symposium as a scholarship recipient from the Alamo Breast Cancer Foundation. In addition, Michele regularly participates in the Advanced Project LEAD pilot program and was asked to be a Project LEAD mentor in July 2017.
Currently serving as the vice-president of the Breast Cancer Care & Research Fund (BCCRF) in Los Angeles, Michele has been enrolled as a consumer reviewer for the DoD's Breast Cancer Research Program, as well as a consumer advocate on multiple Level 3 grant applications. In 2018, Michele became a member of the board of the NBCC and attended the ASCO annual meeting on their behalf. Through the BCCRF, she is presently involved with creating a clinical research/patient advocacy program for underserved high school students.